Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ensartinib Maintenance After Chemoradiation in Stage III Unresectable ALK-Positive NSCLC
ChiCTR2500112211Phase 2Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in non-small cell lung cancer (NSCLC) comparing Ensartinib maintenance arm with Placebo maintenance arm with crossover (2 arms). Primary endpoint: Progression-free survival. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
ensartinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500112211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112211.